Examining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity

Open to people ages 18-65

1. be between the ages of 18 and 65 and provide informed consent;
2. smoke 10 or more combustible cigarettes per day;
3. not seeking treatment for smoking;

1. current use of other smoking cessation aid (bupropion, varenicline, nortriptyline, NRT);
2. more than 3 months of smoking abstinence in past year;
3. use of non-cigarette tobacco product (pipe tobacco, cigars, smokeless tobacco, hookah) or electronic cigarettes in 28-days prior to enrollment;
4. current use of psychoactive drug (excluding cannabis), as determined by urine toxicology;
5. current (past 12-month) DSM-5 diagnosis of substance use disorder for any substances other than tobacco and mild cannabis or alcohol use disorders;
6. lifetime history of psychotic disorders, bipolar disorders, or major depression with suicidal ideation;
7. serious medical illness within past 6 months;
8. have a medical condition that may interfere with safe study participation.
9. renal impairment defined as a creatinine clearance (CrCl) greater than 60 mL/min (estimated with the Cockroft-Gault equation).
10. non-removable ferromagnetic object in body;
11. claustrophobia;
12. serious head injury or period of unconsciousness (more than 30 minutes);
13. more than 250lbs;
14. pregnancy, nursing, or refusal to use reliable birth control if female;
15. have experienced adverse effects to varenicline.